In This Section

Program

Please Note: All session times for the AACR Virtual Meeting: Myeloma – Discovery to Therapy are U.S. Eastern Standard Time (EST).

Monday, April 26, 2021

Tuesday, April 27, 2021

MONDAY, APRIL 26, 2021

Session 1: Disease Progression from Precursor Conditions to Myeloma
Moderators: Irene Ghobrial, Dana-Farber Cancer Institute, Boston, MAssachusetts, and Ola Landgren, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
10-11:20 a.m.

The genomic basis of smoldering multiple myeloma progression
Salomon Manier, University of Lille, Lille, France

Imaging-based predictors of disease progression in early stages of monoclonal plasma cell disorders
Jens Hillengass, Roswell Park Comprehensive Cancer Center, Buffalo, New York

When to treat smoldering myeloma patients?
María-Victoria Mateos, University of Salamanca, Salamanca, Spain

Panel Discussion

Break
11:20-11:35 a.m.
Session 2: Genomics and Epigenetics of Myeloma
Moderator: Brian Walker, Indiana University–Purdue University Indianapolis, Indianapolis, Indiana
11:35 a.m.-12:55 p.m.

Understanding multiple myeloma life history using whole-genome sequencing
Francesco Maura, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida

Biological and therapeutic insights through CRISPR-based studies in myeloma
Constantine Mitsiades, Dana-Farber Cancer Institute, Boston, Massachusetts

The definition of high-risk myeloma
Faith E. Davies, NYU Langone Health, New York, New York

Panel Discussion

TuesDAY, APRIL 27, 2021

Session 3: Myeloma Microenvironment and Immunotherapy
Moderators: Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MASSACHUSETTS, and Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, Massachusetts
10-11:20 a.m.

Emerging insights into immune microenvironment in myeloma
Madhav V. Dhodapkar, Emory University, Atlanta, Georgia

Future advances in adoptive cellular therapy for MM
Eric L. Smith, Dana-Farber Cancer Institute, Boston, Massachusetts

Updates in BiTes and CART: How do we choose the right patient?
Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, New York

Panel Discussion

Break
11:20-11:35 a.m.
Session 4: Novel Therapeutics and Drug Resistance
Moderators: Paola Neri, University of Calgary, Calgary, Alberta, Canada, and Paula Rodríguez-Otero, University of Navarra, Pamplona, Spain
11:35 a.m.-12:55 p.m.

Targeting the BCL2 family in multiple myeloma
Lawrence H. Boise, Emory Winship Cancer Institute, Atlanta, Georgia

Targeted therapies in relapsed/refractory multiple myeloma
Marc S. Raab, Heidelberg University Hospital, Heidelberg, Germany

Novel therapeutics and drug resistance treatment of lenalidomide refractory patients
Francesca Gay, University of Torino, Torino, Italy

Panel Discussion

Break
12:55-1:10 p.m.
Panel Discussion: Bench to Bedside – Application of Lessons Learned from COVID-19 to Clinical Trials and Drug Development in Myeloma
Moderator: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
1:10-2 p.m.

Kenneth C. Anderson
Daniel Auclair, Multiple Myeloma Research Foundation, Norwalk, Connecticut
Nicole J. Gormley, FDA Center for Drug Evaluation & Research, Silver Spring, Maryland
Richard McDonald
Craig L. Tendler, Johnson & Johnson Pharmaceutical R&D, New Brunswick, New Jersey